CSIMarket
 
Voyager Therapeutics Inc   (VYGR)
Other Ticker:  
 
 
Price: $9.2800 $0.15 1.643%
Day's High: $9.41 Week Perf: 2.43 %
Day's Low: $ 9.08 30 Day Perf: 25.92 %
Volume (M): 3,892 52 Wk High: $ 14.34
Volume (M$): $ 36,117 52 Wk Avg: $8.72
Open: $9.09 52 Wk Low: $6.06



 Market Capitalization (Millions $) 413
 Shares Outstanding (Millions) 45
 Employees -
 Revenues (TTM) (Millions $) 250
 Net Income (TTM) (Millions $) 132
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 3

Voyager Therapeutics Inc
Voyager Therapeutics Inc is a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases. The company aims to use gene therapy to deliver potentially transformative treatments directly to the affected areas of the brain. Voyager Therapeutics is developing therapies for diseases such as Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS). The company's approach involves using adeno-associated virus (AAV) vectors to deliver therapeutic genes to specific brain regions. Voyager Therapeutics is conducting clinical trials to evaluate the safety and efficacy of its gene therapies, with the goal of providing new treatment options for patients suffering from these devastating diseases.


   Company Address: 75 Hayden Avenue Lexington 2421 MA
   Company Phone Number: 259-5340   Stock Exchange / Ticker: NASDAQ VYGR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Voyager Therapeutics Inc

Headline: Voyager Therapeutics Inc Surges in Financial Fourth Quarter of 2023

Investors in Voyager Therapeutics Inc (Nasdaq: VYGR) have reason to celebrate as the biotechnology company has turned around its financial performance in the most recent fiscal period. With Income per Share at $1.06 per share, VYGR has shown significant improvement compared to previous reporting periods. Revenue has also doubled by a staggering 1851.907% from the preceding reporting season, leading to a positive net earnings of $56.395 million in the financial fourth quarter of 2023.
The company's focus on improving sales has resulted in a net margin of 62.62% in the financial fourth quarter of 2023, further solidifying its profitability. In the fiscal year 2023, VYGR reported earnings per share of $2.97, a significant increase from the previous fiscal year.

Clinical Study

Breakthrough Gene Therapy Candidate Shows Promise for Friedreich's Ataxia Treatment

Published Mon, Feb 26 2024 12:00 PM UTC

Friedreich's ataxia (FA) is a debilitating genetic neurodegenerative disorder that affects approximately 1 in 50,000 individuals worldwide. Characterized by progressive loss of coordination, muscle weakness, and impaired speech, FA significantly reduces the quality of life for affected individuals. However, a ray of hope shines through recent advancements in gene therapy res...

Clinical Study

Advancements in Tau Silencing Gene Therapy Program for Alzheimer's Disease: Promising Preclinical Results and Favorable Pharmacokinetics

Published Tue, Feb 20 2024 12:00 PM UTC

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of abnormal tau protein in the brain. Voyager Therapeutics, a leading biotechnology company focused on developing gene therapies for neurological diseases, reports robust preclinical activity in their tau silencing gene therapy program for Alzheimer's disease. Additionally, the company...

Shares

Voyager Therapeutics' Lucrative Public Offering Strengthens Shareholder Confidence in Groundbreaking Gene Therapy Innovator.

Published Fri, Jan 5 2024 3:46 AM UTC

Voyager Therapeutics' Successful Public Offering Boosts Shareholder Confidence
LEXINGTON, Mass., Jan. 04, 2024 - Voyager Therapeutics, a pioneering biotechnology company focused on advancing neurogenetic medicines, announced today the successful pricing of its underwritten public offering, marking a significant milestone in the company's growth trajectory. The offering c...

Stock Market Announcement

Voyager Therapeutics Launches Underwritten Public Offering, Empowering Shareholders with Promising Growth Prospects

Published Thu, Jan 4 2024 9:14 PM UTC

Voyager Therapeutics Announces Commencement of Public Offering, Empowering Shareholders
LEXINGTON, Mass., Jan. 04, 2024 - Voyager Therapeutics, Inc. (Nasdaq: VYGR), a leading biotechnology company dedicated to advancing neurogenetic medicines, has made a significant stride towards further growth and innovation. The company proudly announced today that it has commenced ...






 

Voyager Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Voyager Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Voyager Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com